Aziyo Biologics Stock News

Aziyo Biologics (NASDAQ:AZYO) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership. Risk and Volatility Aziyo Biologics has a beta of 0.56, indicating that its stock price is [] The post Aziyo Biologics (NASDAQ:AZYO) & Denali Therapeutics (NASDAQ:DNLI) Financial Contrast appeared first on ETF Daily News .

Vanguard Group Inc. trimmed its holdings in Aziyo Biologics, Inc. (NASDAQ:AZYO) by 14.5% during the second quarter, HoldingsChannel.com reports. The fund owned 55,261 shares of the companys stock after selling 9,358 shares during the period. Vanguard Group Inc.s holdings in Aziyo Biologics were worth $531,000 as of its most recent filing with the Securities and []

Man Group plc trimmed its stake in Aziyo Biologics, Inc. (NASDAQ:AZYO) by 45.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,214 shares of the companys stock after selling 8,368 shares during the period. Man Group plc owned 0.10% of Aziyo Biologics []

SILVER SPRING, Md., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the company will participate in two upcoming virtual investor conferences.

Cantor Fitzgerald reaffirmed their overweight rating on shares of Aziyo Biologics (NASDAQ:AZYO) in a research note published on Thursday morning, Zacks.com reports. Several other brokerages also recently commented on AZYO. Zacks Investment Research downgraded shares of Aziyo Biologics from a hold rating to a sell rating in a research report on Friday, October 29th. Piper []

Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q3 2021 Results - Earnings Call Transcript

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -32.79% and -0.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st

SILVER SPRING, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated p

SILVER SPRING, Md., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated

SILVER SPRING, Md., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated p

Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q2 2021 Results - Earnings Call Transcript

Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q1 2021 Results - Earnings Call Transcript

SILVER SPRING, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pr

SILVER SPRING, Md., April 26, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated

Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q4 2020 Results - Earnings Call Transcript